RealPage Stockholders to Receive $88.75 Per Share in Cash
Transaction Provides Significant Premium to RealPage Stockholders
RICHARDSON, Texas & SAN FRANCISCO–(BUSINESS WIRE)–RealPage, Inc. (NASDAQ: RP), a leading global provider of software and data analytics to the real estate industry, today announced it has entered into a definitive agreement to be acquired by Thoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector, in an all-cash transaction that values RealPage at approximately $10.2 billion, including net debt.
Under the terms of the agreement, RealPage stockholders will receive $88.75 in cash per share of RealPage common stock upon closing of the transaction. The purchase price represents a premium of 30.8% over RealPage’s closing stock price of $67.83 on December 18, 2020, a premium of 36.5% over RealPage’s 30-day volume-weighted average share price through that date, and a premium of 27.8% over RealPage
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
West Fraser and Norbord Announce Mailing of Circulars for Special Meetings of Shareholders
News provided by
Share this article
Virtual shareholder meetings for both West Fraser and Norbord are scheduled for January 19, 2021
Interim order regarding the Arrangement received by Norbord from the Ontario Superior Court of Justice
U.S. and German regulatory approvals received
VANCOUVER, BC and TORONTO, ON, Dec. 21, 2020 /PRNewswire/ - West Fraser Timber Co. Ltd. (
West Fraser ) (TSX: WFT) and Norbord Inc. (
Norbord ) (TSX andNYSE: OSB) today jointly announced that West Fraser s management information circular and Norbord s management proxy circular (together, the
Circulars ), prepared in connection with the previously announced arrangement whereby West Fraser will acquire all outstanding common shares of Norbord (the
Merger Arbitrage Mondays - 5 New Multi-Billion Dollar Deals seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Share:
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx s existing bone franchise
Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of world
Mereo receives $50 million upfront and is eligible for milestones up to $254 million
NOVATO, Calif., LONDON, and REDWOOD CITY, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (NASDAQ:MREO, AIM: MPH)), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human mono